Detection of fetal cell-free DNA in maternal plasma for down syndrome, Edward syndrome and patau syndrome of high risk fetus

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 9525-9530

  Ke, Wei Lin ^a   Zhao, Wei Hua ^a   Wang, Xin Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Down syndrome; Fetal cell free DNA; Prenatal noninvasive diagnosis

Indexed keywords

DNA;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; BLOOD ANALYSIS; CHROMOSOME DELETION; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS OUTCOME; FETUS RISK; HUMAN; KARYOTYPING; MATERNAL PLASMA; PREGNANT WOMAN; PRENATAL DIAGNOSIS; TRISOMY 13;

EID: 84938328622     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. [1] Boormans EM, Birnie E, Wildschut HI, Schuring-Blom HG, Oepkes D, van Oppen CA, Nijhuis JG, Macville MV, Kooper AJ, Huijsdens K, Hoffer MV, Go A, Creemers J, Bhola SL, Bilardo KM, Suijkerbuijk R, Bouman K, Galjaard RJ, Bonsel GJ, van Lith JM. Multiplex ligation-dependent probe amplification versus karyotyping in prenatal diagnosis: the M.A.K.E. Study. BMC Pregnancy Childbirth 2008; 8: 18.
2. [2] Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119: 890-901.
3. [3] Sparks AB, Wang ET, Struble CA, Barrett W, Stokowski R, McBride C, Zahn J, Lee K, Shen N, Doshi J, Sun M, Garrison J, Sandler J, Hollemon D, Pattee P, Tomita-Mitchell A, Mitchell M, Stuelpnagel J, Song K, Oliphant A. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012; 32: 3-9.
4. [4] Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci U S A 1992; 89: 5847-51.
5. [5] Weisz B, Pandya P, Chitty L, Jones P, Huttly W, Rodeck C. Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice. BJOG 2007; 114: 493-497.
6. [6] Rosen T, D’Alton ME. Down syndrome screening in the first and second trimesters: what do the data show?. Semin. Perinatol 2005; 29: 367-75.
7. [7] Fuchs KM, Peipert JF. First trimester Down syndrome screening: public health implications. Semin Perinatol 2005; 29: 267-71.
8. [8] Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS.Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-7.
9. [9] Illanes S, Denbow M, Kailasam C, Finning K, Soothill PW. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev 2007; 83: 563-6.
10. [10] Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218-24.
11. [11] Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, Gerovassili A, Jin Y, Nicolaides KH, Cantor CR, Ding C. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med 2007; 13: 218-23.
12. [12] Hahn S, Zhong XY, Holzgreve W. Recent progress in non-invasive prenatal diagnosis. Semin Fetal Neonatal Med 2008; 13: 57-62.
13. [13] Steinborn A, Rebmann V, Scharf A, Sohn C, Grosse-Wilde H.Placental abruption is associated with decreased maternal plasma levels of soluble HLA-G. J Clin Immunol 2003; 23: 307-314.
14. [14] Watt AH, Legedza AT, Ginsburg ES, Barbieri RL, Clarke RN, Hornstein MD. The prognostic value of age and follicle-stimulating hormone levels in women over forty years of age undergoing in vitro fertilization. J Assist Rep Rod Genet 2000; 17: 264.
15. [15] Lee T, LeShane ES, Messerlian GM, Canick JA, Farina A, Heber WW, Bianchi DW. Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol 2002; 187: 1217-21.